Polypeptide Therapeutic Solutions and PMC Isochem (both headquartered in France) signed a business and technology collaboration agreement in the field of cosmetic and therapeutic polypeptide.
Under the agreement, Polypeptide Therapeutic Solutions will use proprietary technology and research capabilities to offer contract research services from the polypeptide design up to delivery of small quantity of polymer and PMC Isochem will use GMP production facility for clinical batch and commercial supply. In addition, PMC Isochem develops and supplies the strategic high quality Aminoacid N-CarboxyAnhydride raw materials.
Polypeptide Therapeutic Solutions is a company devoted to the design and manufacture of polypeptide-based materials for drug delivery and high-tech applications. Company has more than 20 years of experience in polypeptide & materials science, drug delivery, biological testing, custom manufacturing, quality control and assurance. PTS provides a 360º solution from early research, through scale-up to first preclinical batches, analytical development & validation within a GLP certified laboratory.
PMC Isochem provides product/process development, regulatory approvals, pilot scale and full plant-scale production of drug intermediates and active pharma ingredients (APIs) for major pharmaceutical companies worldwide to serve the needs of Oncology, Cardiovascular, Infectious, Gastro-Intestinal, Neurology and rare diseases. PMC facilities (nearby Paris) are cGMP US-FDA audited plants for manufacturing pharmaceutical products. PMC Isochem operates as a wholly owned subsidiary of PMC Group France.